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tert-Butyl-4-((3-(4-methoxyphenyl)-6-nitro-4-oxo-3,4-dihydroquinazolin-2-
yl)methyl)piperazine-1-carboxylate. Following the same procedure used to synthesize 1, 2-(chloromethyl)-3-(4-methoxyphenyl)-6-nitroquinazolin-4(3H)-one (212 mg, 0.61 mmol) and 1-BOC-piperazine (172 mg, 0.92 mmol) were used to produce the title compound (210 mg, 69%) as a pale-yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ 9.13 (d, J = 2.3 Hz, 1H), 8.55 (dd, J = 9.0, 2.7 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 2H), 2H) , 3.88 (s, 3H), 3.36-3.31 (m, 4H) , 3.30 (s, 2H) , 2.35-2.28 (m, 4H), 1.43 (s, 9H).
2-(Chloromethyl)-6-nitro-3-(thiophen-3-yl)quinazolin-4(3H)-one.
The free amine of thiophen-3-amine was produced from thiophen-3-amine oxalate (Combi-Blocks, ST-4087) by treating it with saturated aq. NaHCO 3 , extracting with CH 2 Cl 2 , drying with Na 2 SO 4 , and then using the resulting clear, light-brown oil in a timely fashion. Following the same procedure used to synthesize 1 (step 2), 2-(2-chloroacetamido)-5-nitrobenzoic acid (241 mg, 0.93 mmol) and thiophen-3-amine (130 mg, 1.31 mmol) were used to produce the title compound (170 mg, 57%) as a black solid. 1 H NMR (400 MHz, CDCl 3 ) δ 9.13 (d, J = 2.5 Hz, 1H), 8.59 (dd, J = 8.9, 2.6 Hz, 1H), 7.90 (d, J = 8.9 Hz, 1H), 7.57 (dd, J = 5.1, 3.2 Hz, 1H), 7.51 (dd, J = 3.2, 1.4 Hz, 1H), 7.11 (dd, J = 5.1, 1.4 Hz, 1H), 4 .34 (br s, 2H).
tert-Butyl-4-((6-nitro-4-oxo-3-(thiophen-3-yl)-3,4-dihydroquinazolin-2-yl)methyl)piperazine-

1-carboxylate.
Following the same procedure used to synthesize 1, 2-(chloromethyl)-6-nitro-3- tert-Butyl-ethyl(2-(methylamino)ethyl)carbamate. Benzaldehyde (0.26 mL, 2.56 mmol) was added dropwise to a solution of (2-aminoethyl)ethylcarbamic acid tert-butyl ester (377 mg, 2.00 mmol) in dry toluene (5 mL) at rt. The reaction flask was equipped with a Dean-Stark trap and a reflux condenser. The mixture was heated at 150 °C for 1.5 hours. After cooling to rt, the DeanStark trap was removed and a solution of methyl p-toluenesulfonate (0.31 mL, 2.05 mmol) in dry toluene (0.5 mL) was added dropwise. The mixture was heated to gentle reflux at 125 °C for 15 hours. After cooling to rt, water (2 mL) was added and the mixture was heated at 80 °C for 30 min.
aq. layer. The product was extracted from the aq. layer with CH 2 Cl 2 (3 x 15 mL), filtered and organic extracts were dried (Na 2 SO 4 ) to give the title compound (171 mg, 42%) as a clear, paleyellow oil, which was used in the next step without further purification.
tert-Butyl-ethyl(2-(methyl((6-nitro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methyl)amino)ethyl)carbamate. Following the same procedure used to synthesize 1, 2- 
Solubility Assessment Protocol
Compound solubility in aqueous solution was measured using an automated kinetic solubility method at the Sanford Burnham Medical Research Institute at Lake Nona. The concentration of the compound in a saturated pH-buffered aqueous solution was determined by UV absorbance (250-498 nm) and compared to the spectra of a precipitation-free reference solution. Aqueous solubility was measured in phosphate buffered saline (PBS) at room temperature (23°C). PBS by definition is 137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate monobasic and a pH of 7.4. Solubility in the TC-83 VEEV CPE assay medium, consisting of high glucose DMEM (Dulbecco's Modified Eagle's Medium) with 10% FBS and 1x Pen/Strep, was also assessed using the same method.
Chemical Stability Assessment Protocol
Compound 45 was evaluated for susceptibility to nucleophilic addition and formation of conjugates by treatment with dithiothreitol (DTT). Supplemental Figure 1 represents the time course experiment with compound 45 under various conditions. The compound was dissolved at 10 µM in PBS at pH 7.4 (1% DMSO) and independently incubated at room temperature with no nucleophile present or 50 µM dithiothreitol (DTT). The test reactions were sampled every hour for eight hours and analyzed by LCMS. The analytical LCMS system utilized for the analysis was a Waters Acquity system with UV-detection and mass-detection (Waters LCT Premier).
The analytical method conditions included a Waters Acquity HSS T3 C18 column (2.1 x 50mm, 1.8 µm) and elution with a linear gradient of 1% water to 100% CH 3 CN at 0.6 mL/min flow rate.
Peaks on the 214 nm chromatographs were integrated using the Waters OpenLynx software.
Absolute areas under the curve were compared at each time point to determine relative percent parent remaining. The masses of potential adducts and dimers of compound 45 were searched for in the final samples to determine if any detectable adduct formed or dimerization had occurred. In the case of compound 45, no adducts were detected at any time point using LCMS detection. All samples were prepared in duplicate. Ethacrynic acid, a known Michael acceptor, was used as a positive control.
Supplemental Figure 1 . Chemical stability of 45 over 8 h in the presence of a 5-fold concentration of dithiothreitol.
Supplemental Table 1 summarizes the percent remaining of 45 at the endpoints of each run in each experiment. The average amount of 45 remaining after 8h when no nucleophile was added was 93.9%, and when 5X DTT was added, nearly 99% of parent 45 remained after the same time period, indicating that 45 was not generally susceptible to degradation or adduct formation in the presence of a thiol-based nucleophile. Aqueous Stability: Supplementla Figure 2 represents the time course experiment with 45 under various aqueous stability conditions. Compound 45 was dissolved at 10 µM in PBS at pH 7.4 (1% DMSO) or dissolved at 10 µM in 50% PBS/50% acetonitrile at pH 7.4 (1% DMSO). The samples were evaluated over 14 timepoints (0, 1, 2, 3, 4, 5, 6, 7, 8, 16, 24, 32, 40 , and 48 h) and analyzed by LCMS. The analytical LCMS system utilized for the analysis was a Waters Acquity system with UV-detection and mass-detection (Waters LCT Premier). The analytical method conditions included a Waters Acquity HSS T3 C18 column (2.1 x 50mm, 1.8 µm) and elution with a linear gradient of 1% water to 100% CH 3 CN at 0.6 mL/min flow rate. Peaks on the 214 nm chromatographs were integrated using the Waters OpenLynx software. Absolute areas under the curve were compared at each time point to determine relative percent parent remaining. In PBS, compound 45 showed and average 82.9% remaining after 48h; however, no other mass peaks were observed. In order to account for precipitation/solubility effects, compound 45 was also evaluated in 50/50 PBS:acetonitrile and was shown to have an average of 96.0% remaining after 48 h (Supplemental Table 2 ). Samples were centrifuged at 3000 rpm for 10 min. The amount of compound in the supernatant was determined by LC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap) and the percent of parent compound remaining after 180 min was calculated by the following formula:
Supplemental
Results reported are the mean of each reaction duplicate, normalized to the internal standard, and expressed as a percent of compound remaining after the incubation time.
Assay details:
• Mouse Plasma in K3 EDTA • Procaine and Procainamide were used as standards. Procaine is highly unstable, Procainamide is highly stable. ] [ stock solutions were initially prepared in 100% DMSO and subsequently diluted in acetonitrile for the assay. The pH of the reactions was kept at ~ 7.4 with potassium phosphate buffer (BD Biosciences, P/N 451201). The reactions were started after adding NADPH to the reaction plate containing microsomes and compounds and time 0 min aliquots were promptly collected and mixed with ice cold acetonitrile (spiked with internal standards) to quench the reactions. The remainder of the reaction volume was incubated at 37 °C with shaking.
Additional aliquots were collected 60 min after the start of the reaction and promptly quenched with ice cold acetonitrile (spiked with an internal standard). Samples were centrifuged at 3000 rpm for 10 min. The amount of compound in the supernatant was determined by LC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap) and the percent of parent compound remaining after 60 min was calculated by the following formula:
All reactions were run in triplicate, except negative controls (no NADPH) which were performed as single reactions. Results reported are the mean of each reaction triplicate, normalized to the internal standard, and expressed as a percent compound remaining after the incubation time.
• Mouse Liver Microsomes: 0.5 mg/mL protein concentration • NADPH Regenerating System: 1.55 mM NADP+, 1.33 mM glucose-6-phosphate,1.33 mM Magnesium chloride, and 0.4 U/mL glucose-6 phosphate dehydrogenase collagen-coated plates (VWR) at ~50,000 cells/well, and incubated in a humidified CO2 incubator at 37 ⁰C. After 4 hrs, the medium was replaced with MFE Support medium (XenoTech). On the third day, the cells were incubated with a range of concentrations (0.01-50 µM) of the test compound. After 24 hrs, cell viability was determined by cellular ATP levels using the Luminescence ATP Detection Assay System (ATPlite 1 step, Perkin Elmer) and the Infinite M200 plate reader (Tecan).
• (Pion Inc.) also containing a surfactant. The permeation time was 60 min. Moderate stirring (equivalent to 40 µm Aqueous Boundary Layer thickness) was applied using the Gut-Box™ (Pion Inc.). The assay DMSO final concentration was 0.5%. After the permeation time, the sandwich was disassembled and the amount of compound present in both the donor and acceptor wells was measured by UV absorbance (250-498 nm) using the Infinite M200 (Tecan US) and compared to spectra obtained from reference standards. Mass balance was used to determine the amount of material embedded in the membrane filter. The effective permeability, Pe, was calculated using the software PAMPA Evolution Plus, version 3.2 (Pion Inc.).
compound as inhibitor of the activity of CYP3A4, CYP2C9, and CYP1A2 was assessed using the P450-Glo™ Assay kits (Promega) in the presence of human liver microsomes (XenoTech). NADPH, a required cofactor for CYP450 metabolism, was provided by the NADPH Regenerating System, Solutions A (BD Biosciences) and B (BD Biosciences).
Compound stock solution was initially prepared in 100% DMSO and subsequently diluted in acetonitrile for the assay. The pH of the reactions was maintained at ~ 7. In vivo brain/plasma exposure assay parameters Supplemental Table 3 In vivo dose-exposure profiling of compound 45 was conducted using the Rapid Assessment of Compound Exposure (RACE) assay as described. 1 Briefly, three independent cohorts of adult male mice (n=3) were subjected to a single IP dose of compound at 1, 5, or 10 mg/kg. Blood was drawn at 20 and 120 min post-administration, and subsequent LC/MS analysis of pooled samples was performed to determine the overall plasma levels of compound. In this abbreviated study, compound 45 was rapidly absorbed with Cmax =20min, followed by decreasing plasma levels observed over time. The compound exhibited a linear relationship between dose and exposure, with estimated AUC (eAUC) that increased in direct proportion to increased dose. At t=120min, compound 45 exhibited significant distribution to the brain suggesting that the compound will reach sufficetly high levels in the target organ tissue necessary to elicit the desired effect in vivo.
Compound 45 was well tolerated. Throughout the study the mice exhibited normal behavior and no signs of adverse effects were observed at any dose.
Materials and methods:
The Rapid Assessment of Compound Exposure (or RACE) assay, is an experiment used in the early phases of discovery to quickly and efficiently determine if the compound of interest is bioavailable. Male C57Bl6j mice, 6-8 weeks of age, ~20g body weight were purchased from the Jackson Laboratory (Bar Harbor, ME) and allowed to acclimate for 3 days. On the day of the study, the compound was formulated a vehicle containing DMSO, Tween80, and sterile water (10:10:80) at 0.1 mg/ml, 0.5mg/ml and 1.0mg/mL) and administered IP to 3 mice at 1 mg/kg, 5 mg/kg or 10 mg/kg. An additional cohort of 3 mice received vehicle as control animals. Blood was collected from the mandibular vein at t= 20min and 120 min post-administration in collection tubes containing sodium EDTA 0.5mM. Whole blood samples were placed on wet ice, immediately after collection, and prior to centrifugation to separate the cellular constituents from plasma. Brain tissues were collected from mice under deep anesthesia at t=120min. LC/MS/MS was used to determine final concentration of compound in plasma and brain homogenate. The protocol described herein was approved by the Sanford Burnham Medical Research Institute at Lake Nona IACUC.
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